Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG Logo
Lonza Group AG
SIX:LONN
Watchlist
Price: 554.2 CHF 2.29% Market Closed
Market Cap: 40B CHF
Have any thoughts about
Lonza Group AG?
Write Note

Lonza Group AG
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lonza Group AG
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Lonza Group AG
SIX:LONN
Total Current Assets
CHf4.9B
CAGR 3-Years
-1%
CAGR 5-Years
11%
CAGR 10-Years
10%
Bachem Holding AG
SIX:BANB
Total Current Assets
CHf747.6m
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
14%
Siegfried Holding AG
SIX:SFZN
Total Current Assets
CHf964.3m
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Tecan Group AG
SIX:TECN
Total Current Assets
CHf847.7m
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Total Current Assets
€326.6m
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Total Current Assets
CHf259.3m
CAGR 3-Years
9%
CAGR 5-Years
260%
CAGR 10-Years
N/A
No Stocks Found

Lonza Group AG
Glance View

Market Cap
40B CHF
Industry
Life Sciences Tools & Services

Amidst the serene valleys and bustling innovation hubs of Switzerland, Lonza Group AG has carved an indelible niche in the dynamic world of life sciences. Established in 1897, this stalwart of the biotech and pharmaceutical industry seamlessly blends traditional Swiss precision with cutting-edge scientific inquiry. Originally a chemical company, Lonza has reinvented itself over the years, today standing as a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and nutrition sectors. From delivering small molecules and complex biologics to pioneering innovations in cell and gene therapy, Lonza's versatile and expansive portfolio underscores its core strength: fostering the seamless transition from early-stage research to full-scale manufacturing. This unique capability leverages a vast network of state-of-the-art facilities and expert talent, enabling Lonza to nurture groundbreaking therapies from concept through to market readiness. The secret to Lonza's business model lies in its adept mix of contract development and manufacturing (CDMO) services, enabling it to partner with a diverse clientele ranging from nimble biotechs to giant pharmaceutical firms. This breadth of collaboration adds a layer of stability and scale to its operations, generating revenue through long-term manufacturing agreements and comprehensive development programs. Lonza thrives on its ability to tailor its offerings, providing customized support at various stages of a drug’s lifecycle — from early discovery to commercial supply. Furthermore, their expansion into high-growth areas such as personalized medicine and biotechnology bolsters their competitive edge while aligning with market demand trends. This strategic alignment, coupled with a relentless pursuit of operational excellence and innovation, propels Lonza's enduring legacy as both a powerhouse and a partner in forging the future of medicine.

LONN Intrinsic Value
495.11 CHF
Overvaluation 11%
Intrinsic Value
Price

See Also

What is Lonza Group AG's Total Current Assets?
Total Current Assets
4.9B CHF

Based on the financial report for Jun 30, 2024, Lonza Group AG's Total Current Assets amounts to 4.9B CHF.

What is Lonza Group AG's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
10%

Over the last year, the Total Current Assets growth was -13%. The average annual Total Current Assets growth rates for Lonza Group AG have been -1% over the past three years , 11% over the past five years , and 10% over the past ten years .

Back to Top